REACH: A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Study Details
Study Description
Brief Summary
This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
This is A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ATG-016-20mg 20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study |
Drug: ATG-016
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
| Experimental: ATG-016-35mg 35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study |
Drug: ATG-016
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
| Experimental: ATG-016-50mg 50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study |
Drug: ATG-016
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
| Experimental: ATG-016-65mg 65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study |
Drug: ATG-016
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
Outcome Measures
Primary Outcome Measures
- MTD in Phase I [16 months]
MTD will be evaluated using the NCI-CTCAE, Version 5.0
- RP2D in Phase I [16 months]
RP2D will be determined under the guidance of the SRC.
- AEs [25 months]
Toxicity will be graded according to the NCI CTCAE, Version 5.0.
- SAEs [25 months]
Toxicity will be graded according to the NCI CTCAE, Version 5.0.
- ORR in Phase II [25 months]
Based on 2006 IWG Response Criteria, evaluated by IRC: ORR (CR + PR + mCR)
Secondary Outcome Measures
- Disease Control Rate (DCR) in Phase I/II [16 months]
DCR (CR + PR + mCR + HI + SD)
- Duration of Response (DOR) in Phase I/II [12 months]
To evaluate duration of response
- Overall Survival (OS） [12 months]
The estimates of Kaplan-Meier
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Understand and voluntarily sign informed Consent (ICF) prior to any assessment/procedure related to study.
-
Age ≥18 years at ICF signature.
-
Estimated life expectancy of minimum of 12 weeks.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature.
-
Subjects must have at least one measurable lesion as defined by RECIST version 1.1.
-
Females of childbearing potential must agree to use effective contraception from the time ICF signature until 180 days after the last dose. Females of childbearing potential include those who are premenopausal and those who are 2 years postmenopausal. Blood pregnancy tests must be negative for female of childbearing potential must have a negative serum pregnancy test at Screening.
Inclusion Criteria Only for Phase Ib study (Dose Escalation and Expansion phase)
- Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have no standard therapy(ies) exists.
Inclusion Criteria Only for Phase II
-
Penile squamous cell carcinomas confirmed by cytology or histology cannot be excised by radical surgery, or postoperative recurrence or metastasis which is not suitable for platinum chemotherapy or platinum resistance or platinum failure.
-
Nasopharyngeal carcinoma
Exclusion Criteria:
Subjects with any of the following conditions will not be enrolled in this study.
-
Central nervous system (CNS) metastases and involvement.
-
A history of bone marrow or organ transplantation.
-
Prior ATG-016 administration or other XPO1 inhibitor treatment.
-
Known to be allergic to the active or inactive ingredients of ATG-016 or drugs with similar chemical structure, or the subject is hypersensitive.
-
Prior therapy with any investigational drugs or systemic anticancer treatment (eg, a period of 5 'half-lives' of drugs, whichever is longer) within 28 days at the time of ICF signature.
-
Received extensive radiation within 28 days at the time of ICF signature or expect to undergo radical radiotherapy during the study period.
-
Received major surgery within 28 days at the time of ICF signature or expect to proceed a major surgical treatment during the study period.
-
Any toxicities unresolved to Grade 1 or baseline from prior anti-tumor therapy (According to NCI-CTCAE 5.0) with the exception of alopecia, within 28 days at the time of ICF signature.
-
Any uncontrolled active infection requiring parenteral treatment of antibiotics, antivirals, or antifungals at the time of ICF signature or within one week of Cycle 1 Day 1 (C1D1). Active hepatitis B virus (HBV) infection (Hepatitis B surface antigen [HBsAg] positive) or active HCV infection (HCV-RNA positive at screening).
-
A history of HIV infection and/or acquired immunodeficiency syndrome.
-
Received immunosuppressive medication within 14 days at the time of ICF signature.
-
Cardiovascular diseases of clinical significance
-
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
-
Have a history of another primary malignancy within 5 years prior to starting study treatment, with following exceptions: malignancy tumors treated by radical therapy and have not been recurred, such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, papillary thyroid carcinoma, etc.
-
Inability or unwillingness to comply with the requirement for oral drug administration, or presence of a gastrointestinal diseases or other clinical conditions that would compromise the absorption of study drug, eg, refractory nausea and vomiting, inability to swallow the formulated product, or previous significant bowel resection, etc.
-
Active or a history of bleeding within 6 months.
-
Received any live attenuated vaccination within 28 days at the signature of ICF.
-
Judgment by the investigator that the subject should not participate in the study by consideration of the complications or other conditions which might affect their adherence to the protocol.
-
Female subjects who are pregnant or lactating.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital of Bengbu Medical College Bengbu | Bengbu | Anhui | China | 233099 |
| 2 | Chongqing Cancer Hospital | Chongqing | Chonqing | China | 400000 |
| 3 | The First Affiliated Hospital of Xiamen University | Xiaomen | Fujian | China | 361000 |
| 4 | West China Hospital, Sichuan University | Chengdu | Sichuan | China | 610044 |
Sponsors and Collaborators
- Shanghai Antengene Corporation Limited
Investigators
- Principal Investigator: Yongsheng Wang, PhD, Guoxue lane, Chengdu, Sichuan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ATG-016-ST-001